<DOC>
	<DOC>NCT00254189</DOC>
	<brief_summary>To determine the ability of a monophasic oral contraceptives ("OC") regimen of Levonorgestrel ("LNG") 90 mg and Ethinyl Estradiol ("EE") 20 mg to inhibit ovulation during 84 days of continuous therapy.</brief_summary>
	<brief_title>Study Evaluating Effects of Levonorgestrel and Ethinyl Estradiol on Ovulation</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Healthy women of legal age of consent who are willing to use a combination OC. Subjects must be under the age of 36 at the time of enrollment (visit 3). Subjects must have had regular (24 to 32 day) menstrual cycles for the 3month period preceding entry into the pretreatment observation cycle, excluding postabortal and nonnursing postpartum subjects. Postabortal and nonnursing postpartum subjects must have completed at least 1 regular (24 to 32 day) spontaneous menstrual cycle before entry into the pretreatment observation cycle. The pretreatment observation cycle for all subjects will begin on day 1 of the subsequent spontaneous menses. Other inclusions apply. A history or the presence of any of the following will prevent enrollment: Thrombophlebitis, thrombosis, or thromboembolic disorders. Deep vein thrombosis. Pulmonary embolism. Other exclusions apply.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Ovulation</keyword>
	<keyword>Oral Contraceptive</keyword>
</DOC>